Scholarlink

<p>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed.</p><p><MediaObject ID="MOESM1"> <VideoObject FileRef="MediaObjects/12325_2025_3366_MOESM1_ESM.mp4" VideoID="A1cXTkHf79jb4EGowLM_XK"> <Caption Language="En" xml:lang="en"> <CaptionContent> <p>Podcast Audio (MP4 169314 KB)</p> </CaptionContent> </Caption> </VideoObject> </MediaObject></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Podcast Synopsis of Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anaemia in Chronic Kidney Disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月23日

查看全文
  • Mario Cozzolino,
  • Sokratis Stoumpos,
  • Sunil Bhandari

摘要

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed.

Podcast Audio (MP4 169314 KB)